Supplement marketing often moves from “this ingredient was studied” to “this product works.” That step skips several important questions.
The Evidence Transfer Problem
Evidence transfers cleanly only when the product, dose, form, population and outcome match the study. Each mismatch weakens the link.
Evidence Distance
| Evidence type | Distance from product claim |
|---|---|
| Trial of the exact product for the claimed outcome | Closest |
| Trial of a standardized ingredient at a known dose | Close |
| Trial of a combination that includes the ingredient | Moderate |
| Different form (capsule vs liquid drops) | Moderate to far |
| Animal or laboratory studies | Furthest |
Combination Products: The Tamarind Example
The tamarind trial often cited for JointVive tested tamarind plus turmeric. Its results cannot be credited to tamarind alone, let alone to a different formula.
Form and Dose: Capsules vs Drops
Pine bark trials used standardized tablets at defined doses. A liquid drop of an undisclosed extract is a different exposure.
Combining Studied Ingredients Does Not Create a Studied Formula
Undisclosed doses inside a blend may fall below studied amounts, and ingredients can interact. Only testing the finished formula answers that.
How We Phrase the JointVive Conclusion
We say JointVive has limited ingredient-level rationale for joint comfort, while direct evidence for the complete formula was not identified. That wording reflects the evidence without overstating or dismissing it.
Sources & References
We prioritize primary product information, regulatory sources, peer-reviewed research and recognized clinical guidance. Seller claims are not treated as independent clinical evidence.
- Tamarind seed + turmeric extract compositions in knee osteoarthritis: randomized trial, 2022 (PMID 35096104)
- Cochrane review: Pine bark (Pinus spp.) extract for treating chronic disorders, 2020
Related Research
Editorial owner: JointVive Reviews Editorial Team · Last reviewed: November 13, 2026